ICE Pharma - Pharmaceutical ingredients, UDCA and bile acid derivatives_Sports

HomeAboutOur BusinessSustainabilityResearch & DevelopmentQuality & ComplianceOur CultureHistoryManagementProductsPharmaceuticalActive Pharmaceutical IngredientsNew Chemical Entities (NCE)Finished Dosage Forms (FDF)ExcipientsDiagnostic / Culture MediaBlood Group AntigensIntermediatesMedical DevicesNutraceuticalBranded ProductsIngredientsResearch ChemicalsCarbohydratesBile AcidsCosmeticsCosmetic RangeCDMO ServicesCarbohydratesFinished Dosage FormsGroup CompaniesABCDextraICE JapanNZPRaichemOthersGlobal PresenceEuropeNorth AmericaSouth AmericaAsiaOceaniaNews & ArticlesBile AcidsBile Acid ChemistryBile Acids In Medicine & BiologyGut Brain AxisBile Acids & The MicrobiomeContact usMenu ×HomeAboutProductsPharmaceuticalView productsNutraceuticalView productsResearch ChemicalsView productsCosmeticsView productsCDMO ServicesFinished Dosage FormsGroup CompaniesABCDextraICE JapanNZPRaichemOthersGlobal PresenceEuropeNorth AmericaSouth AmericaAsiaOceaniaNewsBile AcidsContact Sorry, your browser does not support HTML5 video. The Bile Acids ExpertICE Pharma offers an extensive portfolio of products and services for the pharmaceutical and healthcare markets. We have a unique range of bile acid products and are a leading global integrated producer of Ursodeoxycholic acid (UDCA).View our Product range View our servicesContinue scrollingPharmaceuticalCDMO ServicesNutraceuticalResearch ChemicalsCosmetics Our Group Companies Explore our group companies worldwide Our Japanese company manufactures and commercialises Ursodeoxycholic acid (UDCA) for local and export markets. Our Indian company manufactures and commercialises Ursodeoxycholic acid (UDCA) for the local market. ABC develops and manufactures products for the pharmaceutical, nutraceutical and cosmetics markets, and provides CDMO services. Our New Zealand company produces pharma grade cholic acid and exports a range of bile acid derivatives. Our UK company specialises in carbohydrate chemistry providing products for R&D and contract manufacturing services. Our companyAn unmatched experience and expertiseWith over 70 years of experience and 1500 world-wide employees, ICE Pharma provides both products and services to the pharmaceutical industry.ICE Pharma is an expert in the development and manufacture of bile acid derivatives. We are a leading producer of Ursodeoxycholic Acid (UDCA) with an integrated global manufacturing network in Europe, Latin America, Asia and Oceania that serves customers in over 50 countries.Our five R&D centres have enabled us to develop a unique and comprehensive range products including Generic APIs, Excipients, Finished Dosage Forms and New Chemical Entities.Find out more Our Products & Services We offer a comprehensive & unique range of products & services Learn more Pharmaceutical We offer an extensive range of products for the pharmaceutical market including APIs, Finished Dosage Forms and Excipients. Find out more CDMO Services We provide pharmaceutical contract development and manufacturing services for solid and liquid finished dosage forms and complex carbohydrates Find out more Nutraceutical Our range of branded nutraceutical supplements is focused on strengthening the immune system and gut health. We are also a provider of natural taurine. Find out more Research Chemicals We supply the academic and research communities with complex carbohydrates and novel bile acid derivatives. Find out more Cosmetics Our branded natural cosmetics range is focused on skin care. Find out more Our global footprint Facilities & companies across the globe ICE Pharma has an interconnected network of 7 manufacturing facilities in North and South America, Europe, Asia and Oceania through which we provide our customers with an unparalleled security of supply and a local service.Find out more close South America View South America close North America View North America close Asia View Asia close Europe View Europe close Oceania View Oceania News & ArticlesStay up to date with ICE Pharma’s latest news, events & publications Company HighlightsICEJapan May 3, 2022ICE GROUP acquires Iwaki manufacturing site from Mitbubishi API corporationWe are pleased to announce that on May 2nd ICE Group completed the purchase of the Iwaki Ursodeoxycholic Acid (“UDCA”) manufacturing site from Mitsubishi API Corporation. This transaction represents... Continue reading ArticlesCompany Highlights April 6, 2022Third research publication in collaboration with ICE Pharma and Ferrier Research InstituteSynthesis of Novel C/D Ring Modified Bile Acids Bile acid receptors have been identified as important targets for the development of new therapeutics to treat various metabolic and inflammatory... Continue reading ArticlesCompany Highlights April 1, 2022Bile acids in medicine. Review article by ICE PharmaBile acids: From acient Chinese medicines to modern treatments In 1999 the landscape evolved further when, bile acids and bile salts were shown to have hormonal activity as bile... Continue reading View more news & articles Contact usYour pharmaceutical product or service is just a click away Contact us today and an one of our experts will reply immediately to discuss your requirements. Find out more Products & ServicesPharmaceuticalNutraceuticalResearch ChemicalsCosmeticsCDMO ServicesGroup CompaniesABCDextraICE JapanNZPRaichemOthersGlobal PresenceEuropeNorth AmericaSouth AmericaAsiaOceaniaUseful linksCareersCookies PolicyPrivacy PolicyEthicsTerms & Conditions of salesLegal StatementCopyright ICE S.p.a. 2022 | ICE S.p.a. VAT: IT 01227810353 | ABC Farmaceutici S.p.a. VAT: IT 08028050014 | Riaz S.r.l. VAT: IT 01336600331 | Designed by Dolia.is-menu path.search-icon-path { fill: #ffffff;}body .popup-search-close:after, body .search-close:after { border-color: #ffffff;}body .popup-search-close:before, body .search-close:before { border-color: #ffffff;}